Expectations from Conference , a DD FROM YAHOO BOARD:
* On May 31, 2018. Vivos Inc stated "A veterinary cancer specialist at the University of Missouri—Columbia successfully treated a soft-tissue tumor in the hind thigh of a Sheltie". They are referring to Dr.Maitz. As part of the press report, they also mention ". The status of the dog patient will be followed over the next six months as we evaluate safety and efficacy of yttrium-90-RadioGel treatment". I am 100% sure they are presenting these results next week.
* As part of the report, they say "We anticipate treating another five or more canine subjects in the current test series. With this continuing series of treatments, we will further refine our product labeling and the training that will be provided to veterinarians that want to use our product in the future. We will also be sharing these data as we continue discussions with private veterinary clinic consortium's". Their MoU with Private Veterinary Hospital as Pilot Clinic for Commercial IsoPet® Therapy is inline with their promise in May to study the efficacy of treatment by recruiting more subjects.
* My favorite excerpt from their latest PR release "the company will introduce IsoPet® to the larger veterinarian community at the annual Veterinary Cancer Society Conference to be held in Louisville, KY October 17-20, 2018." IsoPet will be marketed for the first time to the pharma & scientific community backing its value using their research results from successfully treating their animal subjects.
* There will a major PR article next week during/immediately-after the conference.
* Several tweets/messages will be shared with the investors on the acceptance of IsoPet and RadioGel as treatment options for several cancer models.
* Every statement they release will have a credible, well-cited and peer-reviewed research component as a backbone.
RDGL$ will receive major coverage locally and globally starting from this week.
